new glp 1 for weight loss A chapter in GLP-1 treatment is here. Meet Foundayo™ by Eli Lilly, the first FDA-approved oral GLP-1, designed to support through a convenient once-daily approach. Prescription-only treatment, with instant FDA Approves Wegovy Alternative for

F.ChangS

The effect of dietary soy intake on weight loss, glycaemic control, lipid profiles and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome: a randomised clinical trial

Repurposed by Pleiogenix with 4 NIH grants, led to a first-in-class, non-steroid drug for Alcoholic Hepatitis, a $3.B+ mkt without any approved FDA drugs

A 2023 review in the Journal of Clinical Endocrinology & Metabolism highlighted that GLP-1s can delay gastric emptying significantly, especially at higher doses or early in treatment.44 Another study found that just over 5% of patients experience gastroparesis and it was more likely when using liraglutide or dulaglutide when compared with semaglutide.45 A 2024 cross-sectional analysis in Pharmaceuticals examined the GI side effects of semaglutide, dulaglutide, liraglutide, and exenatide in over 10,000 adults with T2DM or obesity from the National Institutes of Health All of Us cohort.45 They found that abdominal pain was the most frequently reported GI issue (57.6%), followed by constipation, diarrhea, nausea/vomiting, GI bleeding, gastroparesis, and pancreatitis